Loading…
Loading…
DECN does not currently pay a dividend.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for DECN and 80,000+ other tickers.
See exactly how DECN's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for DECN and 80,000+ other tickers.
Decision Diagnostics Corp. (DECN), founded in 2000 and based in Westlake Village, California, specializes in developing electronic medical record (EMR) technologies primarily optimized for smartphones. The company provides a wide array of offerings, including both regulated and unregulated diagnostic solutions, as well as home-use testing products for individuals managing chronic illnesses. They also facilitate direct-to-patient logistics for diabetes programs and concentrate on creating mobile-centric e-health products and associated technological innovations. A key part of their product…
Decision Diagnostics (OTCMKTS:DECN - Get Free Report) and 10x Genomics (NASDAQ: TXG - Get Free Report) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, analyst recommendations, profitability, institutional ownership, risk, dividends and earnings. Profitability This table compares Decision Diagnostics and 10x
Privia Health Group (NASDAQ: PRVA - Get Free Report) and Decision Diagnostics (OTCMKTS:DECN - Get Free Report) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, earnings, profitability, analyst recommendations, risk, institutional ownership and dividends. Volatility and Risk Privia Health Group has
Strata Skin Sciences (NASDAQ: SSKN - Get Free Report) and Decision Diagnostics (OTCMKTS:DECN - Get Free Report) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, institutional ownership, risk, dividends, earnings, profitability and analyst recommendations. Valuation and Earnings This table compares Strata
New York, New York--(Newsfile Corp. - March 14, 2021) - Pomerantz LLP announces that a class action lawsuit has been filed against Decision Diagnostics Corporation ("Decision Diagnostics" or the "Company") (OTCMKTS: DECN) and certain of its officers. The class action, filed in United States District Court for the Central District of California, and docketed under 21-cv-00418, is on behalf of a class consisting of all persons and entities other than Defendants that purchased...
NEW YORK, March 12, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Decision Diagnostics Corporation ("Decision Diagnostics" or the "Company") (OTCMKTS: DECN) and certain of its officers. The class action, filed in United States District Court for the Central District of California, and docketed under 21-cv-00418, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Decision Diagnostics securities between March 3, 2020 and December 17, 2020, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.